Winkler, Michael J.
Müller, Philipp
Sharifi, Amin M.
Wobst, Jana
Winter, Hanna
Mokry, Michal
Ma, Lijiang
van der Laan, Sander W.
Pang, Shichao
Miritsch, Benedikt
Hinterdobler, Julia
Werner, Julia
Stiller, Barbara
Güldener, Ulrich
Webb, Tom R.
Asselbergs, Folkert W.
Björkegren, Johan L. M.
Maegdefessel, Lars
Schunkert, Heribert
Sager, Hendrik B.
Kessler, Thorsten http://orcid.org/0000-0003-3326-1621
Funding for this research was provided by:
Corona Foundation (S199/10070/2017)
Deutsche Forschungsgemeinschaft (SFB 1123 B02, TRR267 B06, STRESS_638675)
H2020 European Research Council (759272)
Else-Kröner-Fresenius-Stiftung (2020_EKSE.07)
Deutsche Herzstiftung (F/28/17)
Bundesministerium für Bildung und Forschung (JTC2017_21-040, 6GW0198K)
Deutsches Zentrum für Herz-Kreislaufforschung (Genetic discovery-based targeting of the vascular interface in atherosclerosis)
UCLH Biomedical Research Centre
National Institutes of Health (R01HL125863)
American Heart Association (A14SFRN20840000)
Swedish Research Council (2018-02529)
Hjärt-Lungfonden (20170265)
Fondation Leducq (18CVD02)
Astra-Zeneca (Integrated Cardio Metabolic Centre)
Technische Universität München
Article History
Received: 15 August 2020
Accepted: 26 October 2020
First Online: 13 November 2020
Compliance with ethical standards
:
: H.S. has received personal fees from MSD SHARP & DOHME, AMGEN, Bayer Vital GmbH, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Servier, Brahms, Bristol-Myers-Squibb, Medtronic, Sanofi Aventis, Synlab, Pfizer, and Vifor T as well as grants and personal fees from Astra-Zeneca outside the submitted work. H.S. and T.K. are named inventors on a patent application for prevention of restenosis after angioplasty and stent implantation outside the submitted work. The other authors report no conflict of interest.
: Not applicable.